These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9538159)

  • 21. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma.
    Egberts F; Kotthoff EM; Gerdes S; Egberts JH; Weichenthal M; Hauschild A
    Eur J Cancer; 2012 Mar; 48(5):695-702. PubMed ID: 21917447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysing the serum levels of tumour markers and primary tumour data in stage III melanoma patients in correlation to the extent of lymph node metastases--a prospective study in 231 patients.
    Neuss H; Koplin G; Raue W; Reetz C; Mall JW
    Acta Chir Belg; 2011; 111(4):214-8. PubMed ID: 21954736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography.
    Oberholzer PA; Urosevic M; Steinert HC; Dummer R
    Dermatology; 2008; 217(4):351-5. PubMed ID: 18799883
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B.
    de Lecea MV; Palomares T; Al Kassam D; Cavia M; Geh JLC; de Llano P; Muñiz P; Armesto D; Martinez-Indart L; Alonso-Varona A
    J Eur Acad Dermatol Venereol; 2017 Apr; 31(4):636-642. PubMed ID: 27633490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum protein s100beta in patients with malignant melanoma detected by an immunoluminometric assay.
    Wollina U; Karte K; Hipler UC; Knöll B; Kirsch K; Herold C
    J Cancer Res Clin Oncol; 2000 Feb; 126(2):107-10. PubMed ID: 10664251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
    Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
    Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elevated serum levels of S100 and survival in metastatic malignant melanoma.
    Buer J; Probst M; Franzke A; Duensing S; Haindl J; Volkenandt M; Wittke F; Hoffmann R; Ganser A; Atzpodien J
    Br J Cancer; 1997; 75(9):1373-6. PubMed ID: 9155061
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein.
    Beyeler M; Waldispuhl S; Strobel K; Joller-Jemelka HI; Burg G; Dummer R
    Dermatology; 2006; 213(3):187-91. PubMed ID: 17033166
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients.
    Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U
    J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
    Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
    Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of serum S-100B in malignant melanoma.
    Andrés R; Mayordomo JI; Zaballos P; Rodino J; Isla D; Escudero P; Elosegui L; Filipovich E; Saenz A; Polo E; Tres A
    Tumori; 2004; 90(6):607-10. PubMed ID: 15762365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952.
    Bouwhuis MG; Suciu S; Kruit W; Salès F; Stoitchkov K; Patel P; Cocquyt V; Thomas J; Liénard D; Eggermont AM; Ghanem G;
    Eur J Cancer; 2011 Feb; 47(3):361-8. PubMed ID: 21087856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter evaluation of the analytical and clinical performance of the Elecsys S100 immunoassay in patients with malignant melanoma.
    Alber B; Hein R; Garbe C; Caroli U; Luppa PB
    Clin Chem Lab Med; 2005; 43(5):557-63. PubMed ID: 15899680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
    Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
    Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma.
    Kaskel P; Berking C; Sander S; Volkenandt M; Peter RU; Krähn G
    J Am Acad Dermatol; 1999 Dec; 41(6):962-9. PubMed ID: 10570381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value of pre operative S-100B and SUV in clinically stage III melanoma patients undergoing therapeutic lymph node dissection.
    Kruijff S; Bastiaannet E; Speijers MJ; Kobold AC; Brouwers AH; Hoekstra HJ
    Eur J Surg Oncol; 2011 Mar; 37(3):225-32. PubMed ID: 21277729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse.
    Egberts F; Hitschler WN; Weichenthal M; Hauschild A
    Melanoma Res; 2009 Feb; 19(1):31-5. PubMed ID: 19104452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of S-100B to evaluate therapy effects during bevacizumab induction treatment in AJCC stage III melanoma.
    Kruijff S; Bastiaannet E; Brouwers AH; Nagengast WB; Speijers MJ; Suurmeijer AJ; Hospers GA; Hoekstra HJ
    Ann Surg Oncol; 2012 Feb; 19(2):620-6. PubMed ID: 21861214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of S-100beta assays for the prediction of recurrence and prognosis in patients with AJCC stage I-III melanoma.
    Curry BJ; Farrelly M; Hersey P
    Melanoma Res; 1999 Dec; 9(6):557-67. PubMed ID: 10661766
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: validation by whole body FDG-PET and conventional diagnostics.
    Mruck S; Baum RP; Rinne D; Hör G
    Anticancer Res; 1999; 19(4A):2685-90. PubMed ID: 10470220
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.